$ETRM,EnteroMedics Named One of Fast Company's Top
Post# of 22755
Posted On: 02/16/2016 12:40:45 PM
$ETRM,EnteroMedics Named One of Fast Company's Top Ten Most Innovative Companies in Biotech for 2016
2 hours 37 minutes ago - DJNF
ST. PAUL, Minn., Feb. 16, 2016 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Fast Company has recognized EnteroMedics among the Top 10 Most Innovative Companies in Biotech for 2016.
Dan Gladney, President and Chief Executive Officer of EnteroMedics, stated, "Having brought to market the first new medical device approved by the FDA for the treatment of obesity in over 10 years, EnteroMedics' inclusion on Fast Company's list is validation of the work we have accomplished to date and the vision we have for the future. We continue to work to bring this unique and safe alternative for obesity treatment to patients underserved by the therapeutic options currently available to them."
Most Innovative Companies is one of Fast Company's most significant and highly anticipated editorial efforts of the year, honoring leading enterprises and rising newcomers that exemplify the best in nimble business and impactful innovation. The Most Innovative Companies issue (March 2016) is now available online at www.fastcompany.com/MIC as well as in app form via iTunes, and on newsstands beginning February 23, 2016.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. vBloc(R) Neurometabolic Therapy, delivered by a pacemaker-like device called the Maestro(R) Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics' Maestro Rechargeable System has received U.S. Food and Drug Administration approval, CE Mark and is listed on the Australian Register of Therapeutic Goods.
Information about the Maestro(R) Rechargeable System and vBloc(R) Neurometabolic Therapy
You should not have an implanted Maestro Rechargeable System if you have cirrhosis of the liver, high blood pressure in the veins of the liver, enlarged veins in your esophagus or a significant hiatal hernia of the stomach; if you need magnetic resonance imaging (MRI); if you have a permanently implanted, electrical medical device; or if you need a diathermy procedure using heat. The most common related adverse events that were experienced during clinical study of the Maestro Rechargeable System included pain, heartburn, nausea, difficulty swallowing, belching, wound redness or irritation, and constipation.
Talk with your doctor about the full risks and benefits of vBloc Therapy and the Maestro Rechargeable System. For additional prescribing information, please visit www.enteromedics.com.
If you are interested in learning more about vBloc Therapy, please visit www.vbloc.com or call 1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial sales experience with our Maestro(R) Rechargeable System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and vBloc(R) Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 13, 2015. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/enteromedics-named-one-of-fast-companys-top-ten-most-innovative-companies-in-biotech-for-2016-300220591.html
SOURCE EnteroMedics Inc.
/Web site: http://www.enteromedics.com
(END) Dow Jones Newswires
February 16, 2016 10:03 ET (15:03 GMT)
2 hours 37 minutes ago - DJNF
ST. PAUL, Minn., Feb. 16, 2016 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Fast Company has recognized EnteroMedics among the Top 10 Most Innovative Companies in Biotech for 2016.
Dan Gladney, President and Chief Executive Officer of EnteroMedics, stated, "Having brought to market the first new medical device approved by the FDA for the treatment of obesity in over 10 years, EnteroMedics' inclusion on Fast Company's list is validation of the work we have accomplished to date and the vision we have for the future. We continue to work to bring this unique and safe alternative for obesity treatment to patients underserved by the therapeutic options currently available to them."
Most Innovative Companies is one of Fast Company's most significant and highly anticipated editorial efforts of the year, honoring leading enterprises and rising newcomers that exemplify the best in nimble business and impactful innovation. The Most Innovative Companies issue (March 2016) is now available online at www.fastcompany.com/MIC as well as in app form via iTunes, and on newsstands beginning February 23, 2016.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. vBloc(R) Neurometabolic Therapy, delivered by a pacemaker-like device called the Maestro(R) Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics' Maestro Rechargeable System has received U.S. Food and Drug Administration approval, CE Mark and is listed on the Australian Register of Therapeutic Goods.
Information about the Maestro(R) Rechargeable System and vBloc(R) Neurometabolic Therapy
You should not have an implanted Maestro Rechargeable System if you have cirrhosis of the liver, high blood pressure in the veins of the liver, enlarged veins in your esophagus or a significant hiatal hernia of the stomach; if you need magnetic resonance imaging (MRI); if you have a permanently implanted, electrical medical device; or if you need a diathermy procedure using heat. The most common related adverse events that were experienced during clinical study of the Maestro Rechargeable System included pain, heartburn, nausea, difficulty swallowing, belching, wound redness or irritation, and constipation.
Talk with your doctor about the full risks and benefits of vBloc Therapy and the Maestro Rechargeable System. For additional prescribing information, please visit www.enteromedics.com.
If you are interested in learning more about vBloc Therapy, please visit www.vbloc.com or call 1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial sales experience with our Maestro(R) Rechargeable System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and vBloc(R) Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 13, 2015. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/enteromedics-named-one-of-fast-companys-top-ten-most-innovative-companies-in-biotech-for-2016-300220591.html
SOURCE EnteroMedics Inc.
/Web site: http://www.enteromedics.com
(END) Dow Jones Newswires
February 16, 2016 10:03 ET (15:03 GMT)
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼